

Daniela C Moga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4142808/publications.pdf>

Version: 2024-02-01

57
papers

1,064
citations

567281

15
h-index

414414

32
g-index

60
all docs

60
docs citations

60
times ranked

1885
citing authors

#	ARTICLE	IF	CITATIONS
1	Automated Analysis of Retinal Images for Detection of Referable Diabetic Retinopathy. JAMA Ophthalmology, 2013, 131, 351.	2.5	312
2	Adverse Events Among the Elderly Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 620-627.	1.6	85
3	Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Annals of Neurology, 2017, 81, 549-559.	5.3	83
4	National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (United States), 2016, 95, e3784.	1.0	77
5	Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making. BMJ Evidence-Based Medicine, 2022, 27, 109-119.	3.5	52
6	Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. International Psychogeriatrics, 2018, 30, 1477-1487.	1.0	43
7	Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden. Alzheimer's Research and Therapy, 2017, 9, 36.	6.2	40
8	Risks and Benefits of Bladder Antimuscarinics Among Elderly Residents of Veterans Affairs Community Living Centers. Journal of the American Medical Directors Association, 2013, 14, 749-760.	2.5	34
9	Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 139-148.	3.7	30
10	Patterns and predictors of chronic opioid use in older adults: A retrospective cohort study. PLoS ONE, 2019, 14, e0210341.	2.5	28
11	The Impact of Dementia Diagnosis on Patterns of Potentially Inappropriate Medication Use Among Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1410-1417.	3.6	27
12	Prevalence and Characteristics of Abnormal Head Posture in Children with Down Syndrome: A 20-Year Retrospective, Descriptive Review. Ophthalmology, 2011, 118, 1859-1864.	5.2	25
13	Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents. Pharmacoepidemiology and Drug Safety, 2015, 24, 583-591.	1.9	25
14	Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 1-10.	3.7	19
15	Statin Use and Gastrointestinal Hemorrhage: A Large Retrospective Cohort Study. American Journal of Cardiovascular Drugs, 2019, 19, 65-74.	2.2	17
16	VALIDATION OF TABLET-BASED EVALUATION OF COLOR FUNDUS IMAGES. Retina, 2012, 32, 1629-1635.	1.7	16
17	Intervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer's Symptomatic Expression (INCREASE), a randomized controlled trial: rationale, study design, and protocol. Trials, 2019, 20, 806.	1.6	15
18	A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer's Disease in the US and Finland. Drugs and Aging, 2017, 34, 55-65.	2.7	14

#	ARTICLE	IF	CITATIONS
19	Attitudes toward deprescribing in a middle-aged health disparities population. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1502-1507.	3.0	12
20	Internet-Based Cognitive Behavioral Therapy for Insomnia in Appalachian Women: A Pilot Study. <i>Behavioral Sleep Medicine</i> , 2020, 18, 680-689.	2.1	11
21	One-Year Evaluation of a Targeted Medication Therapy Management Intervention for Older Adults. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 520-528.	0.9	9
22	How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools. <i>BMJ Open</i> , 2021, 11, e043961.	1.9	9
23	An Experimental Education Project for Consultations of Older Adults during the Pandemic and Healthcare Lockdown. <i>Healthcare (Switzerland)</i> , 2021, 9, 425.	2.0	9
24	The value of deprescribing in older adults with dementia: a narrative review. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1367-1382.	3.1	9
25	Primary care clinician and community pharmacist perceptions of deprescribing. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1686-1689.	2.6	8
26	ISPE-Endorsed Guidance in Using Electronic Health Records for Comparative Effectiveness Research in COVID-19: Opportunities and Trade-Offs. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 990-999.	4.7	8
27	Dementia and "Obesity Paradox": Is This for Real or Are We Missing Something? An Epidemiologist's Perspective. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 78-79.	2.5	7
28	Dementia for the Primary Care Provider. <i>Primary Care - Clinics in Office Practice</i> , 2017, 44, 439-456.	1.6	7
29	Mental disorder comorbidity and in-hospital mortality among patients with acute myocardial infarction. <i>Geriatric Mental Health Care</i> , 2015, 3, 7-11.	0.3	5
30	Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma. <i>Healthcare (Switzerland)</i> , 2016, 4, 93.	2.0	5
31	A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2016, 8, 149-158.	1.7	5
32	An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents. <i>BMC Geriatrics</i> , 2017, 17, 295.	2.7	4
33	Potentially Inappropriate Medication Use in Older Adults with Alzheimer's Disease and Related Dementias Living in the Community: A Cross-Sectional Analysis. <i>Drugs - Real World Outcomes</i> , 2021, 8, 519-526.	1.6	4
34	Using administrative data for your research project: 10 considerations before you begin. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 184-187.	1.0	2
35	Case Report: The Complexities of Managing Medications and the Importance of Deprescribing Anticholinergics in Older Adults. <i>Frontiers in Pharmacology</i> , 2021, 12, 584667.	3.5	2
36	An investigation of the concomitant use of angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs and diuretics. <i>European Review for Medical and Pharmacological Sciences</i> , 2015, 19, 2938-44.	0.7	2

#	ARTICLE	IF	CITATIONS
37	An evaluation of injurious falls and Fall-Risk-Increasing-Drug (FRID) prescribing in ambulatory care in older adults. <i>BMC Geriatrics</i> , 2022, 22, 190.	2.7	2
38	Determinants of Sleep Medication Use among Participants in the National Alzheimer's Coordinating Center Uniform Data Set. <i>Journal of Applied Gerontology</i> , 2020, 39, 1340-1349.	2.0	1
39	Intervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer's Symptomatic Expression (INCREASE) Study: Results from a Randomized Controlled Study of Medication Therapy Management Targeting a Delay in Prodromal Dementia Symptom Progression. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, . . .	2.7	1
40	Mental comorbidity and in-hospital mortality among patients with acute myocardial infarction. <i>Value in Health</i> , 2013, 16, A58.	0.3	0
41	Evaluating the incident user design in the HIV population: incident use versus naive?. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 297-300.	1.9	0
42	Difference in Nephrotoxicity Between Nafcillin and Piperacillin-Tazobactam. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
43	Predictors of β -Blocker Initiation After Myocardial Infarction in Patients With Type 2 Diabetes. <i>Journal of Pharmacy Technology</i> , 2016, 32, 160-168.	1.0	0
44	P2-589: PREVALENCE OF POTENTIALLY INAPPROPRIATE MEDICATION USE AND INTERACTIONS IN A PRIVATELY INSURED ELDERLY POPULATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P962.	0.8	0
45	P1-501: PATHOLOGIC ASSOCIATIONS OF POTENTIALLY INAPPROPRIATE MEDICATION USE IN PATIENTS WITH ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P522.	0.8	0
46	P1-514: POTENTIAL IMPACT OF INAPPROPRIATE MEDICATION USE ON PERFORMANCE IN TESTS OF ATTENTION AND EXECUTIVE FUNCTION. <i>Alzheimer's and Dementia</i> , 2018, 14, P528.	0.8	0
47	0979 Internet-Based Cognitive Behavioral Therapy for Insomnia in Appalachian Women: A Pilot Study. <i>Sleep</i> , 2019, 42, A394-A394.	1.1	0
48	Medication-related problems in older adults with and without preclinical Alzheimer's disease: A baseline description from the INCREASE study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044669.	0.8	0
49	Cognitive reserve among potentially inappropriate medication users with and without preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044842.	0.8	0
50	Potentially inappropriate medication use associated with lower mobility reserve among individuals with preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044879.	0.8	0
51	Cognitive reserve for memory performance is mediated by preclinical frontotemporal and limbic amyloid deposition in subjects with normal cognition in early MCI. <i>Alzheimer's and Dementia</i> , 2020, 16, e046569.	0.8	0
52	Potentially inappropriate anticholinergic medication use interacts with memory-enhancing treatment for patients with Alzheimer's disease or related dementias. <i>Alzheimer's and Dementia</i> , 2020, 16, e046675.	0.8	0
53	Potentially inappropriate medications that impact cognition are common in older adults with Alzheimer's disease or related dementias, driven by antipsychotics. <i>Alzheimer's and Dementia</i> , 2020, 16, e046681.	0.8	0
54	Predictors of chronic opioid therapy in Medicaid beneficiaries with HIV who initiated antiretroviral therapy. <i>Scientific Reports</i> , 2021, 11, 15503.	3.3	0

#	ARTICLE	IF	CITATIONS
55	An investigation of new medications initiation during ambulatory care visits in patients with dementia. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 3, 100058.	1.0	0
56	INCREASEâ€™DEPTH: MTM and DEPrescribing THERapy recommendations for medicationâ€™related problems among elderly adults in the INCREASE trial. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
57	Does targeted medication therapy management increase cognitive reserve? Results from the INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimerâ€™s Symptomatic Expression (INCREASE) study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0